Partner Headlines - AMGN

  1. Will Trump Break With Republicans And Push Major Drug Price Reform?

    Investors Business Daily
  2. Actelion Remains In M&A Spotlight, ASH Data In Focus

    TalkMarkets
  3. Trump Vow On Drug Prices Hammers Drug Stocks, But Key Indexes ...

    Investors Business Daily
  4. Rivals Kite Pharma, Juno Therapeutics Tank On Cancer Data; Spark ...

    Investors Business Daily
  5. Guide to American Funds Investment Company of America R2 Fund ...

    TalkMarkets
  6. Amgen, Regeneron 2017 LDL-Busters Could Boost This Small-Cap ...

    Investors Business Daily
  7. Here's How Much Trump Tax Cuts Could Boost The Stock Market

    Investors Business Daily
  8. Bluebird Rockets On Myeloma Drug; Celgene Gets Boost

    Investors Business Daily
  9. Bluebird Bio, Celgene Multiple Myeloma Therapy Shines In 9-Patient ...

    Investors Business Daily
  10. TalkMarkets Presents: Ranjit Thomas - An Overview Of Recent Earnings ...

    TalkMarkets
  11. 6 Worthy Dividend Stocks Down 10% Or More

    TalkMarkets
  12. Morning Call For Thursday, Nov. 17

    TalkMarkets
  13. Biotech Stocks Soar on Election Results, Gilead HBV Drug Approved

    TalkMarkets
  14. Stock Exchange: Is Technical Analysis Effective Post-Election?

    TalkMarkets
  15. Stocks Going Ex Dividend The Third Week Of November

    TalkMarkets
  16. Rayno Biobeat #3…Trump Biotech Rally Leads Market Up

    TalkMarkets
  17. Rayno Biobeat #2…Good Value in Large Cap Biopharmaceuticals

    TalkMarkets
  18. Before The Move: Stocks To Own If Trump Wins

    TalkMarkets
  19. Pricing Issues Continue To Weigh On The Pharma Sector

    TalkMarkets
  20. Fundamentals Remain Strong In The Pharma Sector

    TalkMarkets
  21. Biotech Meltdown: Financial Metrics Offer Few Clues For What ...

    TalkMarkets
  22. Why After A Massive Run, CoLucid Shares Still Look Attractive ...

    TalkMarkets
  23. The U.S. Economy Grew At Its Fastest Pace In Two Years

    TalkMarkets
  24. AskSlim Market Week - 10/28/16

    TalkMarkets
  25. Gilead Sciences, Inc.: Why You Should Go Long On Gilead Stock?

    TalkMarkets
  26. 5 Stocks To Watch After The Market Closes Today - October 27, ...

    TalkMarkets
  27. 5 Stocks To Watch After The Market Closes Today, 10/27/16

    TalkMarkets
  28. Biotech Bear Market Looking For Relief From Q3 Large Cap Growth

    TalkMarkets
  29. Biotech Stock Roundup: Clinical Holds Hit Inovio & Aduro, Vertex ...

    TalkMarkets
  30. 5 Healthcare Stocks To Buy Despite A Clinton Victory

    TalkMarkets
  31. Novartis Tops Q3 Earnings, Misses Sales Estimates

    TalkMarkets
  32. 7 Drug Stocks To Consider As Biosimilars Pick Up Pace

    TalkMarkets
  33. Swing Trading Watch List - October 11, 2016

    TalkMarkets
  34. Earnings ESP

    TalkMarkets
  35. Rayno 2016 Life Science Portfolio Update

    TalkMarkets
  36. Ligand Pharma Dives After Out-Licensed Drug Misses Study Goal

    TalkMarkets
  37. Amgen's Multiple Myeloma Drug Bumbles Key Test Vs. Blockbuster ...

    IBD
  38. Biosimilars In Limelight On FDA Approval Of Amgen Drug

    TalkMarkets
  39. Stocks Extend Gains; Facebook Up On Positive Analyst Chatter

    IBD
  40. Stocks Up After 1st Presidential Debate; Why Tesla Looks Healthiest ...

    IBD
  41. Biotech ETFs Lead Q3 Rally: XBI Breaks Out

    TalkMarkets
  42. 2 Biotech Funds Leading Nascent Bull Market: Which Is Right For ...

    Investors Business Daily
  43. QQQ ETF Posts 52-Week High; Energy Stocks Sag As Oil Drops To ...

    Investors Business Daily
  44. What's Driving The Biotech Stock Rally? And Will It Last?

    Investors Business Daily
  45. Are Biotechs Finally Making A Comeback? Here Are 5 Must-Watch ...

    Investors Business Daily
  46. Apple, Facebook, Alphabet, Amazon, Ford, McDonald's Headline ...

    Investors Business Daily
  47. Amgen Beats Q2 Earnings Estimates, Raises Guidance

    Investors Business Daily
  48. Facebook, GoPro, Amgen Beat; Whole Foods Disappoints

    Investors Business Daily
  49. Nasdaq Up As Fed Stands Pat On Rates; Will Apple Break Its Downtrend?

    Investors Business Daily
  50. Alder Biopharma Migraine Drug Holds Up After 6 Months

    Investors Business Daily
  51. This Week Could Decide Whether Biotech ETFs' Rally Sizzles Or ...

    Investors Business Daily
  52. Week In Review: Stock Breakouts, Netflix Subs Snub, Tesla's Plan, ...

    Investors Business Daily
  53. Lilly, J&J, Novo Battle For Diabetes Market Heats Up; FDA Rulings ...

    Investors Business Daily
  54. Chardan Upgrades Regeneron Amid Relative Underperformance To ...

    Benzinga
  55. Gilead, Johnson & Johnson or Roche?

    GuruFocus
  56. Amgen, Celgene Buck Short Interest Trend In Biotech Stocks

    Benzinga
  57. Chardan: Sell Regeneron After Sanofi Drops Patent Infringement ...

    Benzinga
  58. The Generic Drug Battle

    Benzinga
  59. Regeneron Q4 Earnings Miss Estimates Amid Slow Praluent Launch

    IBD
  60. Schoenebaum: Biotech P/Es Show 'Buying Signal' With Caveat; Amgen, ...

    Benzinga
  61. Pharmaceuticals Turn To Politics To Protect Prices

    Benzinga
  62. Leerink Is Back On Board The Biotech Train

    Benzinga
  63. LinkedIn Downgraded; Biotechs Initiated; Tableau PT Cut

    IBD
  64. Plenty of Opportunity to Buy Individual Stocks: John Buckingham

    GuruFocus
  65. Maybe Some Good News For A Big Biotech ETF

    Benzinga
  66. Why Amazon, Microsoft, Xerox And Amgen Are Moving After-Hours

    Benzinga
  67. Earnings Recap For January 28

    Benzinga
  68. FDA Accepts Amgen's Biosimilar Biologics License Application ...

    Benzinga
  69. Regeneron Is Now A Sell For Chardan

    Benzinga
  70. Big Earnings Expectations For Big Biotech

    Benzinga
  71. Amgen's Vectibix, Best Supportive Care Improves Overall Survival ...

    Benzinga
  72. Amgen's Repatha) Approved in Japan as First PCSK9 Inhibitor for ...

    Benzinga
  73. Medicines Company Spikes On Report Of Possible Sale

    IBD
  74. Jim Cramer Likes Amgen

    Benzinga
  75. Write A Prescription For This Healthcare ETF

    Benzinga
  76. Stocks Reverse Higher To Big Gains; Intel Falls After Q4 Results

    IBD
  77. Stocks, Mutual Funds Rose In Q4 Despite Dec. Woes

    IBD
  78. Jim Cramer Gives His Opinion On Lockheed Martin And Gilead Sciences

    Benzinga
  79. 3 Potential Blockbuster Drugs Launching in 2016

    IBD
  80. Mid-Afternoon Market Update: Netflix Drops Following Baird Downgrade; ...

    Benzinga
  81. Mid-Day Market Update: Baxalta Shares Surge Amid Report Of Shire ...

    Benzinga
  82. Mid-Morning Market Update: Markets Open Lower; Tesla Motors Delivers ...

    Benzinga
  83. Benzinga's Top #PreMarket Gainers

    Benzinga
  84. Alan Fournier Sells GM, Buys Molson Coors Brewing

    GuruFocus
  85. The 5 Top-Performing Big-Cap Drug Stocks Of 2015

    IBD
  86. Dividend Growth Skids To Halt For S&P 500

    IBD
  87. 5 Guru Picks in Volatile Biotech Industry

    GuruFocus
  88. Benzinga's M&A Chatter for Monday December 21, 2015

    Benzinga
  89. Big Cap 20 Stocks Setting Up In Bases

    IBD
  90. Analyzing Amgen's Dividend Hike

    GuruFocus
  91. 3 Biotechs Atlantic Equities Loves And 1 It's Avoiding

    Benzinga
  92. Piper Jaffray Makes 15 'Provocative' Predictions For Biopharma ...

    Benzinga
  93. EC Approves Amgen's IMLYGIC as First Oncolytic Immunotherapy ...

    Benzinga
  94. 4 Top Dividend Plays To Help Cure Stock Price Blues

    IBD
  95. Big Biotech Amgen Facing Pivotal Year In 2016

    IBD
  96. Allergan Among Health Care Holdings in Alan Fournier's Portfolio

    GuruFocus
  97. Benzinga's Top Upgrades

    Benzinga
  98. Benzinga's Top #PreMarket Gainers

    Benzinga
  99. Amgen Shares Move Higher Following Morgan Stanley Upgrade To ...

    Benzinga
  100. Amgen Submits Application to EMA To Expand Indication Of Kyprolis ...

    Benzinga
Trading Center